Pharma Mar SA (PHM) – Strategy, SWOT and Corporate Finance Report
- Pages: 48
- Published: May 2023
- Report Code: MLPH140326FSA
Pharma Mar SA (PHM) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
Pharma Mar SA (Pharma Mar) discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.
Scope
• Detailed information on Pharma Mar SA required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Pharma Mar SA in the form of a SWOT analysis
• An in-depth view of the business model of Pharma Mar SA including a breakdown and examination of key business segments
• News about Pharma Mar SA, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Pharma Mar SA and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Pharma Mar SA as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Pharma Mar SAs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Oryzon Genomics SA
CTI BioPharma Corp
Traslational Cancer Drugs Pharma SL
Ability Pharmaceuticals SL
GP Pharm SA
Ariad Pharmaceuticals (Spain) SL
GP Pharm SA
Ability Pharmaceuticals SL
Ariad Pharmaceuticals (Spain) SL
CTI BioPharma Corp
Traslational Cancer Drugs Pharma SL
Oryzon Genomics SA
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.